Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.
Oriola’s Q3 was broadly solid quarter. However, profitability remained at the comparison period’s level, weighed down by a one-off inventory impairment. On a positive note, Kronans Apotek continued to make progress towards improved performance.
Higher freight costs and increased operating expenses weighed on Oriola's earnings in Q2. Meanwhile, associate company Kronans improved its result compared with the corresponding period last year.
Oriolas Q2-regnskab var operationelt en smule svagere end vores forventninger, da selskabets justerede EBITDA forblev på niveau med sammenligningsperioden og var lidt lavere end vores estimater.
